Pretreatment risk stratification for non-metastatic head and neck squamous cell carcinoma in a high-prevalence area  by Hsieh, Yao-Yu et al.
Available online at www.sciencedirect.comJournal of the Chinese Medical Association 74 (2011) 487e492
www.jcma-online.comOriginal Article
Pretreatment risk stratification for non-metastatic head and neck squamous
cell carcinoma in a high-prevalence area
Yao-Yu Hsieh a,d, Peter Mu-Hsin Chang b,d, Ming-Huang Chen b,d, Pen-Yuan Chu c,d,
Cheng-Hwai Tzeng b,d, Shyue-Yih Chang c,d, Po-Ming Chen b,d, Muh-Hwa Yang b,e,*
aDivision of Hematology and Oncology, Taipei Medical University-Shuan-Ho Hospital, New Taipei City, Taiwan, ROC
bDivision of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
cDepartment of Otolaryngology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
dNational Yang-Ming University School of Medicine, Taipei, Taiwan, ROC
e Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC
Received January 12, 2011; accepted June 7, 2011AbstractBackground: This retrospective study was to establish a prognostic scoring system for patients with non-metastatic head and neck squamous cell
carcinoma (HNSCC).
Methods: The medical records of 151 patients with HNSCC were evaluated. Clinical data were collected and statistical analyses were performed
to determine the prognostic value of pretreatment variables and to build a risk stratification system. Analysis of the data for 94 additional patients
validated the risk stratification system.
Results: Three independent adverse prognostic factors were identified: Age <65 years, LDH  upper normal limit and performance status. The
risk stratification was defined as two or more adverse factors presented at diagnosis versus one adverse factor or no adverse factors. Patients with
two or more adverse factors had a shorter survival regardless of treatment. This was confirmed in both the training set and the validation set.
Conclusion: This risk stratification provides additional information to the current tumor staging system, which could be useful in making
decisions for individual patients and selecting more homogenous patients when designing clinical trials.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
Keywords: albumin; head and neck squamous cell carcinoma; lactate dehydrogenase; prognosis1. Introduction
Head and neck squamous cell carcinoma (HNSCC) is one of
the major cancers in Taiwan, where its incidence is the most
increased among all cancers. It ranks fourth in cancer incidence
and cancer-related deaths among men.1 This is most likely the
result of habitual chewing of betel nuts by middle-aged men.2
A multi-disciplinary approach, including surgery, radiotherapy,
and chemotherapy, is the mainstay for treating patients with* Corresponding author. Dr. Muh-Hwa Yang, Institute of Clinical Medicine,
National Yang-Ming University School of Medicine, 155, Section 2, Li-Nong
Street, Taipei 112, Taiwan, ROC.
E-mail address: mhyang2@vghtpe.gov.tw (M.-H. Yang).
1726-4901/$ - see front matter Copyright  2011 Elsevier Taiwan LLC and the C
doi:10.1016/j.jcma.2011.09.003HNSCC. Some pretreatment factors had been reported to predict
poor prognosis, such as co-morbidity index determined by the
Adult Comorbidity Evaluation-27 (ACE-27) score,3 hyper-
calcemia,4e7 pre-treatment hematologic profile, or prolonged
facial edema.8,9 Other factors have also been shown to be asso-
ciatedwith a poor prognosis in various kinds of cancer other than
HNSCC, such as tumor-related leukocytosis,10 pretreatment
anemia,11e15 pretreatment thrombocytosis,16e23 levels of
pretreatment serum albumin24,25 and serum lactate dehydroge-
nase (LDH),26e28 and hypercalcemia.29 Some molecular
prognostic factors, such as, human papilloma virus 16
(HPV-16),30e33 vascular endothelial growth factor (VEGF),31
and epidermal growth factor receptor (EGFR)31,33 were also
recently reported to influence the prognosis of HNSCC.hinese Medical Association. All rights reserved.
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prognosis of patients with advanced HNSCC is still lacking.
Risk stratification is important in cancer treatment because
it provides information that may be used to select the most
appropriate therapeutic approach. Several well-known risk
stratification systems are applied worldwide today.26,27,29
Other risk stratification systems based on prognostic factors
also assist physicians to more confidently select treatment
strategies; furthermore, they facilitate the selection of more
homogenous patient groups for clinical trials.34e37 Given the
predictive efficacy demonstrated for the factors described
above, we elected to apply a similar model to locally advanced
HNSCC. We focused on pretreatment clinical factors as they
are easily obtained and reproducibly measured.
2. Methods2.1. Training set of the risk stratificationWe retrospectively reviewed the charts of 158 patients with
primary HNSCC diagnosed by pathology in the Taipei
Veterans General Hospital from December 2002 to May 2006.
All patients’ personal profiles were de-linked during statistical
analyses. Patients with nasopharyngeal carcinoma were
excluded. Patients with medical conditions associated with
reactive leukocytosis or thrombocytosis, such as acute or
chronic inflammatory diseases, or anemia related to acute
blood loss were excluded.8 Patients with distant metastases at
the time of diagnosis, or metastatic squamous cell carcinoma
other than the head and neck were also excluded, as our goal
was to establish a risk-scoring model for nonmetastatic
HNSCC only. We ultimately enrolled 152 patients. Pretreat-
ment clinical data, such as age, sex, site of primary tumor,
TNM staging of tumor according to the American Joint
Committee on Cancer (AJCC) staging system sixth edition,38
concentrations of LDH and serum calcium, ECOG perfor-
mance status (ECOG PS),39 ACE-27 score,3 and hematologic
profile (white blood cell count, differential count, hemoglobin
level, and platelet count) were collected. All 152 patients
underwent definitive treatment for HNSCC. Overall survival
(OS) was estimated from the day of diagnosis to the last
follow-up date or death. The median follow-up time was 24.3
months (range 0.2 months to 83.2 months).2.2. Definition of pre-treatment parameters used in
univariate analysisTo facilitate the statistical analysis, we further assigned
patients to different categories: age (<65 years of age vs. 65
years of age), ECOGPS (0e1 vs.2), ACE-27 (score 0 vs. score
1e3), definitive treatment (surgical vs. non-surgical), T stage
(T3 þ T4 vs. T1 þ T2), N stage (N0 vs. Nþ, i.e., N1e3) and
overall stage (stage IeIII vs. stage IV, since there was no
significance between stage I to III in the individual log-rank test).
We defined hypoalbuminemia as serum albumin3.5 g/dL.24,25
Hypercalcemia was defined as a corrected serum calcium
concentration >10 mg/dL.29 Elevated serum LDH was definedas a serumLDH concentration> the upper limit of normal range
(ULN).26,27 Tumor-related leukocytosis was defined as a pre-
treatment white blood cell count (WBC) > 10  109 cells/L in
the absence of known inflammatory or infectious diseases.
Tumor-related thrombocytosis was defined as a pretreatment
platelet count of >400  109 cells/L in the absence of known
inflammatory conditions.10,16,17 Monocytosis was defined as
a monocyte count>1 109 cells/L as reported in a recent study
published by our group.8 A hemoglobin concentration of
<11 g/dL in the absence of acute blood loss was defined as
tumor-related anemia.12,132.3. Validation set for the scoring systemWe applied the prognostic scoring system among patients
with nonmetastatic HNSCC diagnosed from July 2006 to
December 2008. A total of 94 patients were evaluated
according to this scoring system.2.4. Statistical analysisThe Kaplan-Meier method was used for survival analysis,
and the log-rank test was used for univariate analysis of
prognostic factors. A p value <0.05 by the two-tailed test was
considered to indicate statistical significance. To test the
independent prognostic effect of variables that showed
significance in univariate analysis by the log-rank test, the Cox
proportional hazards model was applied. The relative risk of
survival analysis indicates the risk of death with reference to
the first item of each analysis. The correlations of variables
were analyzed by Chi-square test or Fischer’s exact test, as
appropriate. The survival endpoint was OS and was measured
from the date of diagnosis to the date of death or last follow-
up. All statistical analyses were performed by SPSS software
(version 13.00, SPSS Inc, Chicago, IL, USA).
3. Results3.1. Patient characteristics and univariate analyses of
prognostic factorsThe pretreatment clinical characteristics of 151 patients
with HNSCC are shown in Table 1. Only one patient with
a diagnosis of salivary gland squamous cell carcinoma was
excluded from analysis because of limited numbers (n ¼ 1).
The median follow-up time was 24.5 months (0.5 months to
83.2 months). Fourteen variables were analyzed, and 11
variables showed adverse prognostic effects on survival. These
adverse prognostic factors were enrolled into the multivariate
analysis. Sex, hypercalcemia, and site of primary tumor did
not exhibit any impact on survival.3.2. Multivariate analysis for independent prognostic
factorsThe eleven variables that showed p values <0.05 in the log-
rank test were tested with multivariate Cox regression analysis
Table 1
Patient characteristics and univariate analysis of prognostic factors in 151
patients with non-metastatic head and neck squamous cell carcinoma.
Variables Patients (%) Overall survival p (log rank)
Median (mo) 3-y (%)
Age (y)
65 50 (33.1%) Not reached 80.2 0.018a
<65 101 (66.9%) Not reached 57.6
Gender
Male 136 (90.1) Not reached 64.3 0.593
Female 15 (9.9) Not reached 72.7
LDH (U/L)
Normal 115 (76.2) Not reached 72.1 <0.001a
>ULN 34 (22.5) 16 42.5
Unknown 2 (1.3)
Albumin (g/dL)
>3.5 135 (89.4) Not reached 67.5 0.002a
3.5 14 (9.3) 8.8 45.8
Unknown 2 (1.3)
Calcium (mg/dL)
Normal 131 (86.8) Not reached 66.2 0.234
>10 18 (11.6) Not reached 57.8
Unknown 2 (1.3)
ECOG PS
<2 126 (83.4) Not reached 73.2 <0.001a
2 24 (15.9) 9.0 13.4
Unknown 1 (0.7)
ACE-27 score
0 90 (59.6) Not reached 71.1 0.017a
1e3 61 (40.4) Not reached 56.5
Site b
Oral 57 (37.7) Not reached 70.5 0.127
Oropharynx 16 (10.6) Not reached 80.0
Hypopharynx 49 (32.5) Not reached 50.6
Larynx 29 (19.2) Not reached 69.9
T stage
T1 þ T2 61 (40.4) Not reached 78.1 0.015a
T3 þ T4 90 (59.6) Not reached 56.2
Lymph node
Negative 71 (47.0) Not reached 80.0 <0.001a
Positive 80 (53.0) 29.0 50.3
Stage
I 6 (4.0) Not reached 83.3 0.006a
II 32 (21.2) Not reached 79.9
III 35 (23.2) Not reached 72.9
IV 78 (51.6) 26.4 49.4
Stage
IþIIþIII 73 (48.4) Not reached 76.4 0.001a
IV 78 (51.6) 26.4 49.4
WBC (109 cells/L)
<10 134 (88.7) Not reached 67.6 0.014a
10 17 (11.3) 18.0 45.6
Monocytes (109 cells/L)
<1 135 (89.4) Not reached 69.4 0.001a
1 10 (6.6) 9.1 26.7
Unknown 6 (4.0)
Hemoglobin (g/dL)
11.0 130 (86.1) Not reached 67.6 0.041a
<11.0 21 (13.9) 23.1 49.9
Table 1 (continued )
Variables Patients (%) Overall survival p (log rank)
Median (mo) 3-y (%)
Platelets (109 cells/L)
<400 135 (89.4) Not reached 68.8 0.001a
400 11 (7.3) 9.7 17.0
Unknown 5 (3.3)
ACE-27 score ¼ adult comorbidity evaluation-27 score; ECOG PS ¼ Eastern
Cooperative Oncology Group performance status; LDH ¼ lactate dehydro-
genase; T stage ¼ tumor spread or tumor size; ULN ¼ upper limit of normal
range; WBC ¼ white blood cell count.
a p value <0.05.
b Only one patient was diagnosed with salivary gland squamous cell carci-
noma and was excluded from analysis due to limited numbers (n ¼ 1).
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(Table 2). Three factors independently showed significant
adverse impacts on survival: age <65 years ( p < 0.001, 95%
CI 2.197e16.290), serum LDH > ULN ( p ¼ 0.004, 95% CI
1.48e6.838), and ECOG PS 2 or greater ( p < 0.001, 95% CI
2.257e11.993).3.3. Risk stratification based on prognostic factorsWe then categorized the 151 patients into two groups
according to their independent adverse factors. Patients with two
or more adverse factors were categorized into the high-risk
group. All other patients were categorized into the low-risk
group. Two patients with missing values for these clinical
characteristics were excluded from the analysis. Patients with
two or more adverse factors had significantly shorter rates of
survival (Fig. 1, low-risk groups vs. high-risk groups, p< 0.001).
The 3-year OS rates in the low- and high-risk groupswere 75.4%
and 17.8%, respectively. Themedian survival was not reached in
the low-risk group andwas 9.1months in the high-risk group.We
then analyzed survival according to the treatment administrated.
Among patients who received definitive surgical intervention,
thosewith two ormore adverse factors had a significantly shorter
survival rate than those without any adverse factors or with only
one adverse factor (Fig. 2A, low-risk group vs. high-risk group,
p < 0.001). The 3-year OS rates in the low-risk and high-risk
groups were 79.7% and 23.1%, respectively. Among patients
who received nonsurgical definitive intervention, this stratifica-
tion also predicted a better survival rate for patients without any
adverse factors or with only one adverse factor (Fig. 2B, low-risk
vs. high-risk group, p < 0.001). The 3-year OS in the low-risk
and high-risk groups were 77.1% and 14.3%, respectively. In
subgroup analysis based on patients in the same stage, this risk
stratification model significantly predicted worse survival
among patientswith stage III and stage IVHNSCC (3-year OS in
the low-risk and high-risk groups 83.8% vs. 40.0%, respectively,
p¼ 0.003; 69.7%vs. 5.9%, respectively, p< 0.001; Figs. 3A and
3B). In patientswith stage IIHNSCC, therewas a strong trend for
better 3-year OS in the low-risk group versus the high-risk group
(82.6% vs. 50.0%, respectively, p ¼ 0.087, data not shown).
Therewere too few patients with stage I HNSCC (total n¼ 6) for
statistical analysis to be performed.
Table 2
Multivariate analysis of prognostic factors by Cox’s proportional hazards
method in 151 patients with non-metastatic head and neck squamous cell
carcinoma.
Factors Relative risk 95% CI p
Age (y)
65 1.000 2.197e16.290 <0.001a
<65 5.983
LDH (U/L)
Normal 1.000 1.448e6.838 0.004a
>UNL 3.146
Serum albumin (g/dL)
>3.5 1.000 0.917e6.656 0.074
3.5 2.470
ECOG PS
<2 1.000 2.257e11.993 < 0.001a
2 5.203
ACE-27 score
0 1.000 0.974e3.945 0.059
1e3 1.961
T stage
T1 þ T2 1.000 0.792e3.720 0.171
T3 þ T4 1.716
Lymph node
Negative 1.000 0.739e3.989 0.208
Positive 1.718
Stage
Stage IþIIþIII 1.000 0.576e3.112 0.498
Stage IV 1.339
WBC (109 cells/L)
<10 1.000 0.391e2.982 0.882
10 1.080
Monocytes (109 cells/L)
<1 1.000 0.423e4.362 0.607
1 1.359
Hemoglobin (g/dL)
11.0 1.000 0.463e2.504 0.865
<11.0 1.076
Platelets (109 cells/L)
<400 1.000 0.202e1.942 0.417
400 0.626
ACE-27 score ¼ adult comorbidity evaluation-27 score; CI ¼ confidence
interval; ECOG PS ¼ Eastern Cooperative Oncology Group performance
status; LDH ¼ lactate dehydrogenase; T stage ¼ tumor spread or tumor size;
UNL ¼ upper normal limit; WBC ¼ white blood cell counts.
a p value <0.05.
Fig. 1. Kaplan-Meier-estimated overall survival curves for the two risk groups,
as derived from analysis of data for 151 patients with locally invasive head and
neck squamous cell carcinoma ( p < 0.001, log-rank test).
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further applied it among patients diagnosed with nonmetastatic
HNSCC from July 2006 toDecember 2008.A total of 94 patients
were enrolled in the validation set. Themedian follow-up time in
this set was 27.9 months (range 0.8months to 43.6 months). This
stratification predicted a better rate of survival among patients in
the low-risk group (low-risk vs. high-risk groups,p¼ 0.003). The
3-year survival rates were 83.5%and 60.6%, respectively. Again,
among patients who received definitive surgical intervention, the
low-risk group had a significantly longer survival rate than thehigh-risk group (low-risk vs. high-risk groups, p ¼ 0.039).
Among patients who received nonsurgical definitive interven-
tion, this scoring system also predicted a better rate of survival for
low-risk patients (low-risk vs. high-risk groups, p ¼ 0.028). In
subgroup analysis, there were only 14 patients with stage III
HNSCC. Patients in the low-risk group still showed better 3-year
OS than patients in the high-risk group (100% vs. 50.0%,
respectively, p¼ 0.016). Patients with low-risk stage IVHNSCC
showed a longer survival than patients in the high-risk group (3-
year OS in the low-risk and high-risk groups, 78.4% vs. 61.4%,
respectively, p ¼ 0.029). Since there were only 4 patients with
stage I or II HNSCC, statistical analysis was not performed.
4. Discussion
In this study, we attempted to create a model based on
prognostic factors for the stratification of patients with non-
metastatic HNSCC into more homogenous groups, facilitating
a more accurate prediction of the outcome and the selection of
more homogenous patient groups for clinical trials. The two
major primary cancer sites of our patients were the oral cavity
and the hypopharynx, which are consistent with our nationwide
population data.1 Firstly, we identified 11 prognostic factors
with clinical effects on survival. Most of the identified factors
were in accordance with previous reports, with the exception of
hypercalcemia.3,8,28 Hypercalcemia has been reported to be
a poor prognostic factor but showed no prognostic effect in our
univariate analysis.4e7 However, if we analyzed the original
158 patients regardless of distant metastases, the results were
statistically significant ( p ¼ 0.013, data not shown). Further-
more, among the 7 patients with metastatic HNSCC, 5 (71.4%)
presented initially with hypercalcemia. This result suggests that
the patients with HNSCC who presented with hypercalcemia
were likely to have distant metastases. In addition, we
demonstrated four novel prognostic factors that have never
been reported for HNSCC: age <65 years, LDH greater than
ULN, hypoalbuminemia, and ECOG PS 2 or greater.
Fig. 2. Survival analysis for two risk groups according to the primary treatment modalities, showing the adverse impact on survival in high-risk patients whether the
patient had received definitive surgical intervention (A) or not (B) (both p < 0.001).
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were predisposed toward a poor histopathology of their
HNSCC (Chi-square test, p ¼ 0.026, data not shown). In
comparison with other factors, age <65 years was associated
with a predisposition toward having a higher rate of lymph node
involvement and higher platelet count (Chi-square test,
p ¼ 0.001; Mann-Whitney U test, p ¼ 0.017, respectively, data
not shown). This may explain why the survival of patients <65
years of age was worse. Although serum LDH was included in
a prognostic scoring system established by Cheng et al for
nasopharyngeal cancer,28 no association has been reported for
HNSCC. The situation with hypoalbuminemia is similar.24,25
In the multivariate analysis, only age <65 years,
LDH > ULN, and ECOG PS 2 or greater were independent
risk factors for nonmetastatic HNSCC. Other prognostic
factors, including ACE-27 score 1e3,3 lymph node involve-
ment, hypoalbuminemia, T stage 3e4, tumor-related leukocy-
tosis, anemia, thrombocytosis, or monocytosis, which have
been previously reported to be associated with poor prognosis,8
showed no significance in the multivariate analysis.
We then assigned these risk factors into two risk categories
and showed the feasibility of predicting clinical outcome for
patients with nonmetastatic HNSCC. Furthermore, this strati-
fication clearly predicted a group of patients with short
survival rates despite administration of definitive treatment
(Figs. 2A and 2B). In the validation test, this stratification also
predicted the poor outcomes of those patients with two orFig. 3. Survival analysis for two risk groups according to the stage showing the adve
(B) ( p ¼ 0.003, p < 0.001, respectively).more adverse factors. Again the predictive ability was not
influenced by the administration of definitive treatment. In the
subgroup analyses based on the same stage, this risk stratifi-
cation also identified a group of patients with worse survival in
the same stage, especially in stage III and stage IV (Fig. 3).
These results showed that our risk stratification can add
information in addition to the current staging system, both in
the training and the validation set.
The limitation of our study is its retrospective nature. The
median survival times were not reached in the low-risk groups
in either the training set or the validation set.
We have determined that combining three independent
prognostic factors (age, LDH, and ECOG performance status)
provides a statistically verifiable basis for risk stratification,
with distinct clinical characteristics and outcomes demon-
strated for each of the good- and poor-risk groups. Cheng et al
has established a prognostic model for patients with naso-
pharyngeal cancer, but it focuses on locoregional control and
was obtained for nasopharyngeal cancer only.28 Our results
proved that the scoring system established in this study was
not influenced by the administered treatment and may add
additional information to the current staging system.
In conclusion, this is the first study to establish a risk-
stratification scoring system for predicting prognosis among
patients with nonmetastatic HNSCC. This model for risk strati-
fication based on prognostic factorsmayprove efficacious for the
selection of more homogenous patient cohorts for clinical trials.rse impact on survival in high-risk group patients with stage III (A) or stage IV
492 Y.-Y. Hsieh et al. / Journal of the Chinese Medical Association 74 (2011) 487e492Acknowledgments
The authors thank Dr. Liu Chun-yu for his assistance in
statistical analysis and editing of figures.References
1. Department of Health. The executive Yuan cancer registry annual report
in Taiwan area 2007.
2. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC. Betel quid
chewing, cigarette smoking and alcohol consumption related to oral
cancer in Taiwan. J Oral Pathol Med 1995;24:450e3.
3. Piccirillo JF, Costas I, Claybour P, Borah AJ, Grove L, Jeffe D. The
measurement of comorbidity by cancer registries. J Regist Manag 2003;
30:7.
4. Toro C, Rinaldo A, Silver CE, Politi M, Ferlito A. Paraneoplastic
syndromes in patients with oral cancer. Oral Oncol 2010;46:14e8.
5. Chapireau D, Adlam D, Cameron M, Thompson M. Paraneoplastic
syndromes in patients with primary oral cancers: a systematic review. Br J
Oral Maxillofac Surg 2010;48:338e44.
6. Alsirafy SA, Sroor MY, Al-Shahri MZ. Hypercalcemia in advanced head
and neck squamous cell carcinoma: prevalence and potential impact on
palliative care. J Support Oncol 2009;7:154e7.
7. Ferlito A, Elsheikh MN, Manni JJ, Rinaldo A. Paraneoplastic syndromes
in patients with primary head and neck cancer. Eur Arch Otorhinolaryngol
2007;264:211e22.
8. Chen MH, Chang PM, Chen PM, Tzeng CH, Chu PY, Chang SY, et al.
Prognostic significance of a pretreatment hematologic profile in patients
with head and neck cancer. J Cancer Res Clin Oncol 2009;135:
1783e90.
9. Chen MH, Chang PM, Chen PM, Tzeng CH, Chu PY, Chang SY, et al.
Prolonged facial edema is an indicator of poor prognosis in patients with
head and neck squamous cell carcinoma. Support Care Cancer 2010;18:
1313e9.
10. Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, Ohyashiki K.
Tumor-related leukocytosis is linked with poor prognosis in patients with
lung carcinoma. Cancer 2001;92:2399e405.
11. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic
factor for survival in patients with cancer: a systemic, quantitative review.
Cancer 2001;91:2214e21.
12. Dunst J, Kuhnt T, Strauss HG, Krause U, Pelz T, Koelbl H, et al. Anemia
in cervical cancers: impact on survival, patterns of relapse, and association
with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 2003;56:
778e87.
13. Becker A, Stadler P, Lavey RS, Hansgen G, Kuhnt T, Lautenschlager C,
et al. Severe anemia is associated with poor tumor oxygenation in head
and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2000;
46:459e66.
14. Baghi M, Wagenblast J, Hambek M, Moertel S, Gstoettner W,
Strebhardt K, et al. Pre-treatment haemoglobin level predicts response and
survival after TPF induction polychemotherapy in advanced head and
neck cancer patients. Clin Otolaryngol 2008;33:245e51.
15. Rades D, Schild SE, Bahrehmand R, Zschenker O, Alberti WA, Rudat VR.
Prognostic factors in the nonsurgical treatment of esophageal carcinoma
with radiotherapy or radiochemotherapy: the importance of pretreatment
hemoglobin levels. Cancer 2005;103:1740e6.
16. Pedersen LM, Milman N. Diagnostic significance of platelet count and
other blood analyses in patients with lung cancer. Oncol Rep 2003;10:
213e6.
17. Brockmann MA, Giese A, Mueller K, Kaba FJ, Lohr F, Weiss C, et al.
Preoperative thrombocytosis predicts poor survival in patients with glio-
blastoma. Neuro Oncol 2007;9:335e42.
18. Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y,
Hayashi H, et al. Thrombocytosis associated with poor prognosis in
patients with esophageal carcinoma. J Am Coll Surg 2004;198:
737e41.19. Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC, et al.
Impact of pretreatment thrombocytosis on survival in primary breast cancer.
Thromb Haemost 2003;89:1098e106.
20. Suzuki K, Aiura K, Kitagou M, Hoshimoto S, Takahashi S, Ueda M, et al.
Platelet counts closely correlate with the disease-free survival interval of
pancreatic cancer patients. Hepatogastroenterology 2004;51:847e53.
21. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, et al.
Poor prognosis associated with thrombocytosis in patients with gastric
cancer. Ann Surg Oncol 2002;9:287e91.
22. Lu CC, Chang KW, Chou FC, Cheng CY, Liu CJ. Association of
pretreatment thrombocytosis with disease progression and survival in oral
squamous cell carcinoma. Oral Oncol 2007;43:283e8.
23. Chen CC, Chang JY, Liu KJ, Chan C, Ho CH, Lee SC, et al. Hepato-
cellular carcinoma associated with acquired von Willebrand disease and
extreme thrombocytosis. Ann Oncol 2005;16:988e9.
24. Kim JE, Yoo C, Lee DH, Kim SW, Lee JS, Suh C. Serum albumin level is
a significant prognostic factor reflecting disease severity in symptomatic
multiple myeloma. Ann Hematol 2010;89:391e7.
25. Sun LC, Chu KS, Cheng SC, Lu CY, Kuo CH, Hsieh JS, et al. Preoper-
ative serum carcinoembryonic antigen, albumin and age are supplemen-
tary to UICC staging systems in predicting survival for colorectal cancer
patients undergoing surgical treatment. BMC Cancer 2009;9:288.
26. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-
Saez R, et al. Follicular lymphoma international prognostic index. Blood
2004;104:1258e65.
27. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al.
The revised International Prognostic Index (R-IPI) is a better predictor of
outcome than the standard IPI for patients with diffuse large B-cell
lymphoma treated with R-CHOP. Blood 2007;109:1857e61.
28. Cheng SH, Tsai SY, Horng CF, Yen KL, Jian JJ, Chan KY, et al. A
prognostic scoring system for locoregional control in nasopharyngeal
carcinoma following conformal radiotherapy. Int J Radiat Oncol Biol
Phys 2006;66:992e1003.
29. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treat-
ment outcome and survival associated with metastatic renal cell carci-
noma of non-clear-cell histology. J Clin Oncol 2002;20:2376e81.
30. Goon PK, Stanley MA, Ebmeyer J, Steinstrasser L, Upile T, Jerjes W,
et al. HPV & head and neck cancer: a descriptive update. Head Neck
Oncol 2009;1:36.
31. Fei J, Hong A, Dobbins TA, Jones D, Lee CS, Loo C, et al. Prognostic
significance of vascular endothelial growth factor in squamous cell
carcinomas of the tonsil in relation to human papillomavirus status and
epidermal growth factor receptor. Ann Surg Oncol 2009;16:2908e17.
32. Sedaghat AR, Zhang Z, Begum S, Palermo R, Best S, Ulmer KM, et al.
Prognostic significance of human papillomavirus in oropharyngeal squa-
mous cell carcinomas. Laryngoscope 2009;119:1542e9.
33. Kong CS, Narasimhan B, Cao H, Kwok S, Erickson JP, Koong A, et al.
The relationship between human papillomavirus status and other molec-
ular prognostic markers in head and neck squamous cell carcinomas. Int J
Radiat Oncol Biol Phys 2009;74:553e61.
34. Merkel S, Bialecki D,Meyer T, Mu¨ller V, Papadopoulos T, HohenbergerW.
Comparison of clinical risk scores predicting prognosis after resection of
colorectal liver metastases. J Surg Oncol 2009;100:349e57.
35. Cadili A, McKinnon G, Wright F, Hanna W, MacIntosh E, Abhari Z, et al.
Validation of a scoring system to predict non-sentinel lymph node
metastasis in melanoma. J Surg Oncol 2010;101:191e4.
36. Reissfelder C, Rahbari NN, Koch M, Ulrich A, Pfeilschifter I, Waltert A,
et al. Validation of prognostic scoring systems for patients undergoing
resection of colorectal cancer liver metastases. Ann Surg Oncol 2009;16:
3279e88.
37. Liao CT, Huang SF, Chen IH, Chang JT, Wang HM, Ng SH, et al. Risk
stratification of patients with oral cavity squamous cell carcinoma and
contralateral neck recurrence following radical surgery. Ann Surg Oncol
2009;16:159e70.
38. Greene FL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M, et al
(eds). AJCC cancer staging manual. New York: Springer-Verlag; 2002.
39. Orr ST, Aisner J. Performance status assessment among oncology
patients: a review. Cancer Treat Rep 1986;70:1423e9.
